Clinical Trial

A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

Study acronym: ICTOS
Completed
View on ClinicalTrials.gov →
Summary
Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-29.
Status change: Recruiting → Completed 2026-01-09
Trial Details
NCT Number NCT07009262
Lead Sponsor KalVista Pharmaceuticals, Ltd.
Collaborators: US Hereditary Angioedema Association
Conditions Hereditary Angioedema
Enrollment 88 participants
Start Date 2025-04-21
Primary Completion 2025-11-25 (estimated)
Study Completion 2025-11-25 (estimated)
Updated on ClinicalTrials.gov 2026-01-13